Obesity
News
Earlier colorectal cancer screening appears cost-effective in overweight, obese patients
Starting colonoscopy at age 45 seems to be cost-effective for both men and women.
Feature
Best diets in 2023: Mediterranean diet wins again
U.S. News & World Report’s latest annual rankings of the best diet plans has been released.
News
FDA approves Wegovy (semaglutide) for obesity in teens 12 and up
FDA approves semaglutide 2.4mg (Wegovy), a once-weekly subcutaneous injection, for treating obesity in adolescents aged 12 years and older.
From the Journals
Does vitamin D deficiency cause obesity or vice versa?
A strong link exists between low vitamin D levels (serum 25[OH] vitamin D) and obesity.
From the Journals
FMT doesn’t appear to affect weight loss after bariatric surgery
There is much interest in the gut microbiota as a potential target for the treatment of obesity. FMT from a lean donor has shown promise in...
Feature
‘The Whale’: Is this new movie fat-phobic or fat-friendly?
Brendan Fraser wears prosthetics to portray a 600-lb man in “The Whale,” sparking controversy from activists around the casting decision.
Feature
Bite-sized bouts of exercise: Why they are valuable and what they are missing
Short, intense bursts of physical activity offer entry into exercise for less active individuals.
Feature
Cancer researcher banned from federal funding for faking data in nearly 400 images in 16 grant applications
The former basic medical sciences professor will be banned from receiving federal grants for a decade.
Opinion
The new obesity breakthrough drugs
Semaglutide and other drugs for weight loss were being developed for improving glucose regulation and unexpectedly were found to achieve...
Commentary
Does paying people to lose weight work?
Thousands of genes and dozens of hormones are involved in our individual levels of hunger, cravings, and fullness.
From the Journals
Low-carb, high-fat, calorie-unrestricted diet improves type 2 diabetes
The benefits of the diet were seen regardless of a person’s calorie intake.